Oncology News

Ivosidenib modestly extended OS among patients with previously treated isocitrate dehydrogenase 1-mutated advanced cholangiocarcinoma, according to final results of the phase 3 ClarIDHy trial presented at Gastrointestinal Cancers Symposium.

An allogeneic chimeric antigen T-cell therapy showed evidence of clinical activity among patients with metastatic colorectal cancer, according to results of a dose-escalation study presented at Gastrointestinal Cancers Symposium.

Pembrolizumab monotherapy demonstrated superior PFS and PFS2 compared with standard-of-care chemotherapy among patients with microsatellite-instability high/mismatch repair-deficient metastatic colorectal cancer.

The FDA granted priority review to retifanlimab for treatment of certain patients with squamous cell carcinoma of the anal canal, according to the agent’s manufacturer.

Circulating tumor DNA analysis outperformed an established biomarker in predicting risk for colorectal cancer recurrence after surgery, according to study results presented at Gastrointestinal Cancers Symposium.

Employing community health workers to increase the number of cervical cancer and colorectal cancer screenings was a cost-effective strategy in certain circumstances, according to a recent analysis.

The gut microbiome potentially could serve as a biomarker to predict the efficacy of nivolumab among patients with advanced gastric cancer, according to results of the DELIVER trial presented at Gastrointestinal Cancers Symposium.

Treatment disparities mediated about one-third of OS differences observed between white and Black patients with stage IV colorectal cancer, according to a retrospective cohort study presented at Gastrointestinal Cancers Symposium.

Body weight loss may predict poor outcomes among patients with metastatic gastric or gastroesophageal junction cancer receiving third-line or later treatment, according to study results presented at Gastrointestinal Cancers Symposium.

The FDA granted priority review to nivolumab for two gastrointestinal cancer indications, according to the agent’s manufacturer.